Selank Peptide UK: Research Evidence - Peptides UK
Selank Peptide UK: Scientific Identity, Research Evidence and UK Regulation
Selank is a synthetic seven-amino-acid peptide derived from research into tuftsin, a naturally occurring immunoregulatory fragment. It has attracted interest in anxiety, neurotransmission, cognition and immune signalling, but the published evidence is limited, geographically concentrated and insufficient to establish Selank as an approved treatment in the UK.
Direct Answer
Selank is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly shortened to TKPRPGP. It was designed as an extended analogue of tuftsin, the naturally occurring tetrapeptide Thr-Lys-Pro-Arg.
Laboratory and animal research has examined Selank in relation to GABAergic signalling, enkephalin-degrading enzymes, brain-derived neurotrophic factor, gene expression, learning and stress-related behaviour. These findings remain mechanistic or preclinical and do not demonstrate a medical benefit in people.
Several small Russian-language human studies reported changes in anxiety rating scales, quality-of-life measures or brain functional connectivity. However, the evidence does not include the large, independently replicated, placebo-controlled trials normally expected for UK approval.
No UK marketing authorisation for Selank or Selank acetate was identified in the official medicine sources searched for this article. It should not be presented as an approved UK treatment for anxiety, cognitive impairment, depression or another health condition.
Selank Peptide Key Points
The most important distinctions for interpreting Selank research responsibly.
What Is Selank?
Selank is a synthetic peptide derived from the sequence of the natural immune-associated peptide tuftsin.
Tuftsin is a tetrapeptide with the sequence Thr-Lys-Pro-Arg. It was originally identified as a fragment associated with the Fc region of immunoglobulin G and has been investigated for effects on immune-cell activity.
Selank retains the four-residue tuftsin sequence and adds Pro-Gly-Pro to its C-terminal end. The resulting sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro.
The added Pro-Gly-Pro sequence belongs to a group of short proline-containing peptides sometimes described as glyprolines. Researchers developed this extension to alter peptide stability and biological behaviour compared with the shorter parent fragment.
Online articles frequently call Selank an “anxiolytic” or “nootropic”. These words describe the areas in which it has been investigated. They should not be interpreted as evidence that Selank is an approved anxiety medicine or clinically established cognitive treatment in the UK.
Selank in the Peptides UK Research Market
Commercial descriptions often move further than the available evidence.
Selank has become increasingly visible in Peptides UK search results, where it is frequently sold as a lyophilised powder or discussed alongside Semax and other experimental neuropeptides.
Product pages commonly associate it with calmness, focus, mood, memory, sleep or stress. These descriptions often rely on animal experiments, small Russian-language studies or proposed molecular pathways.
A product page may also fail to distinguish between Selank free peptide, Selank acetate, N-acetyl Selank and amidated derivatives. These are not chemically identical materials.
A research name does not define the finished product
“Selank” on a vial does not establish the exact chemical form, peptide amount, counterion, impurity profile, aggregation state, sterility, endotoxin level or relationship to the material used in a published study.
History and Development of Selank
The peptide emerged from Russian research into short regulatory peptides and tuftsin analogues.
Tuftsin Research
Investigators studied the tetrapeptide Thr-Lys-Pro-Arg because of its relationship with immunoglobulin-derived immune signalling.
Creation of the Seven-Residue Analogue
Researchers added Pro-Gly-Pro to the tuftsin sequence to form Thr-Lys-Pro-Arg-Pro-Gly-Pro, now commonly known as Selank.
Early Enzyme and Behaviour Studies
Research examined whether Selank altered enkephalin-degrading enzymes and behaviour in mouse and rat experimental models.
Small Human Anxiety Studies
Russian research groups published comparative and add-on studies involving patients with anxiety-spectrum and somatoform diagnoses.
Gene-Expression and Brain-Imaging Research
Later experiments examined GABA-related gene expression in animal tissue and functional brain connectivity in healthy adult volunteers.
Current Online Research Market
Selank is now widely marketed by international peptide sellers despite the absence of UK authorisation and major gaps in product-specific human safety evidence.
Molecular and Scientific Profile
Accurate identification begins with the full seven-residue sequence and declared chemical form.
Selank Free Peptide
The sequence is commonly written as H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH or TKPRPGP.
Extended Tuftsin Analogue
Tuftsin contributes the first four residues: Thr-Lys-Pro-Arg.
The Pro-Gly-Pro extension creates the seven-residue Selank molecule and distinguishes it from natural tuftsin.
| Common name | Selank |
|---|---|
| Alternative terms | Selanc; Selank peptide; Selank acetate may also be described as TP-7 |
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Single-letter sequence | TKPRPGP |
| Peptide length | Seven amino-acid residues |
| Free-peptide molecular formula | C33H57N11O9 |
| Free-peptide molecular weight | Approximately 751.9 g/mol |
| Related endogenous sequence | Tuftsin, Thr-Lys-Pro-Arg |
| Confirmed single receptor | No universally accepted specific Selank receptor has been established |
Selank, Selank Acetate and Modified Selank Are Not the Same
Commercial naming can hide meaningful chemical differences.
| Name | Simplified Chemical Description | Important Distinction |
|---|---|---|
| Selank free peptide | H-TKPRPGP-OH | The unmodified seven-residue peptide |
| Selank acetate | Selank associated with acetate as a salt or counterion | Acetate is not the same as covalent N-terminal acetylation |
| N-acetyl Selank | Ac-TKPRPGP-OH | Contains a covalent acetyl group at the N-terminus |
| N-acetyl Selank amidate | Ac-TKPRPGP-NH2 | Contains both N-terminal acetylation and C-terminal amidation |
Research conducted using Selank should not automatically be applied to a modified derivative. Terminal acetylation, amidation and salt formation can affect molecular mass, charge, solubility, enzymatic stability and biological behaviour.
Certificate warning
A certificate that states only “Selank acetate” without a sequence, observed molecular mass and acetate result may not distinguish a simple acetate salt from an N-acetylated peptide.
How Is Selank Thought to Act in Research Models?
Several mechanisms have been proposed, but none has been established as a complete explanation in humans.
GABA-Related Signalling
Gamma-aminobutyric acid, or GABA, is the principal inhibitory neurotransmitter in the mammalian brain. Because conventional anxiety medicines can affect GABA signalling, researchers have examined whether Selank influences related pathways.
A 2016 rat study reported correlations between gene-expression changes following Selank and those following GABA exposure. The authors proposed that modulation of the GABAergic system could contribute to Selank’s observed effects in animals.
A separate experiment using human neuroblastoma cells found that Selank did not directly alter the messenger-RNA levels of the selected GABAergic-system genes in that cell model. The results show why the mechanism should not be reduced to a simple claim that Selank “raises GABA”.
Enkephalin-Degrading Enzymes
Enkephalins are naturally occurring opioid peptides involved in pain, stress and emotional signalling. In-vitro studies reported that Selank inhibited enzymes involved in enkephalin breakdown.
Mouse research also associated changes in enkephalin degradation with behavioural effects in some strains but not others. Variation between strains suggests that biological responses may depend on genetic or physiological context.
Brain-Derived Neurotrophic Factor
BDNF is a protein involved in neuronal survival, adaptation and synaptic plasticity. Rat studies reported changes in hippocampal BDNF expression or content following Selank exposure.
These animal findings do not establish that Selank improves memory, mood or neurological health in humans. BDNF changes can differ according to brain region, timing, experimental stress and disease model.
Gene Expression and Immune Signalling
Experiments have reported changes in genes associated with neurotransmission, chemokines, cytokines and inflammatory pathways. A small human study also measured changes in cytokine balance among participants with anxiety-asthenic diagnoses.
Cytokine changes are biological observations rather than proof of a clinically useful immune effect. Immune signalling is complex, and increasing or decreasing one marker cannot be described automatically as beneficial.
What Human Research Exists for Selank?
The human literature is larger than for many research peptides but remains inadequate for firm clinical conclusions.
Selank and Phenazepam
A 2014 Russian-language publication described a comparative study involving 60 patients with phobic-anxiety and somatoform diagnoses.
The authors reported changes in anxiety measures and quality of life. The accessible abstract does not establish the level of randomisation, allocation concealment or placebo control expected in a modern confirmatory trial.
Selank With Phenazepam
A 2015 study compared 30 patients receiving phenazepam alone with 40 receiving phenazepam plus Selank.
Because both groups received an active benzodiazepine medicine and Selank was used as an add-on, the design cannot establish the independent effect of Selank with the certainty of a placebo-controlled monotherapy trial.
Enkephalin Metabolism
A 2008 publication involving participants with generalised anxiety disorder or neurasthenia measured the half-life of leu-enkephalin alongside clinical variables.
The study reported changes during Selank exposure, but a biochemical association does not establish an approved treatment effect.
Cytokine Measurements
A related publication reported changes in Th1 and Th2 cytokine balance over a short study period.
The work did not establish long-term clinical significance, disease prevention or a general immunomodulatory benefit.
Why These Studies Are Not Definitive
The human studies were generally small, produced by a relatively concentrated group of institutions and published largely in Russian-language journals.
Public abstracts provide incomplete information about randomisation, placebo use, blinding, allocation concealment, preregistered outcomes and handling of missing data.
Independent replication in larger, internationally registered trials was not identified. The studies therefore generate hypotheses but do not meet the evidence standard required to present Selank as a proven UK treatment.
Comparative evidence is not the same as approval evidence
A study can report a difference between groups without establishing that the intervention has a favourable long-term benefit-to-risk balance, consistent manufacturing or effectiveness across different populations.
Selank Brain-Imaging Research
Functional-connectivity findings are mechanistic observations rather than treatment outcomes.
A 2020 publication examined resting-state functional connectivity in 52 healthy participants exposed to Selank or the related peptide Semax.
The analysis focused on predefined brain regions including the amygdala and dorsolateral prefrontal cortex. These regions are associated with emotional processing and executive functions.
The study reported changes in functional connectivity after peptide exposure. However, functional magnetic resonance imaging measures statistical relationships between signals in different brain areas. It does not show that a person’s anxiety, memory or mental health has improved.
The publication was brief, and the publicly available abstract does not provide enough detail to establish clinical relevance, duration of change or reproducibility.
Animal Research on Selank
Most mechanistic and behavioural evidence comes from mouse and rat experiments.
Learning and Memory Models
Rat studies have examined learning tasks, object recognition and experimentally induced memory impairment. Some reported differences in selected behavioural outcomes after Selank exposure.
Animal learning tasks are useful for examining neural hypotheses but do not reproduce human cognitive disorders, education, work performance or everyday memory.
Stress and Anxiety-Like Behaviour
Selank has been studied in open-field, elevated-maze and chronic-stress models. Responses varied by animal strain, experimental conditions and the type of stress imposed.
“Anxiety-like behaviour” in a rodent is an operational laboratory measurement. It is not the same as a clinical diagnosis of generalised anxiety disorder, panic disorder or post-traumatic stress disorder.
Alcohol-Related Models
Research has examined Selank during experimental alcohol exposure and withdrawal in rats. Studies reported differences in behaviour, memory measures and BDNF content under selected conditions.
These studies do not establish Selank as a treatment for alcohol dependence or withdrawal in humans.
Parkinsonism and Other Neurological Models
Animal studies have explored Selank in chemically induced Parkinson-like states and other models of nervous-system disturbance.
Such work is exploratory. A chemically induced animal model cannot reproduce the full pathology, progression and treatment needs of a human neurodegenerative condition.
Laboratory and In-Vitro Selank Research
Cell and enzyme experiments help identify possible pathways but cannot establish clinical effectiveness.
Enkephalin Degradation
Selank inhibited selected enkephalin-degrading enzymes in human serum and other experimental systems.
GABA-Related Genes
Researchers measured changes in selected gene transcripts after Selank exposure in animal tissue and cultured cells.
Cytokines and Chemokines
Experiments reported altered expression of inflammation-related genes and immune-signalling molecules.
Proline-Rich Fragments
Studies have examined how the Pro-Gly-Pro portion may contribute to peptide stability or downstream biological responses.
Laboratory evidence boundary
Enzyme inhibition, altered messenger RNA or a cytokine change in a dish does not prove that Selank produces a safe or useful outcome in the human brain or immune system.
Selank Evidence at a Glance
The current research record contains signals of biological activity but substantial uncertainty.
| Research Question | Evidence Type | Current Status | Main Limitation |
|---|---|---|---|
| Is Selank a chemically defined peptide? | Sequence databases and analytical chemistry | Yes, when the exact form is declared | Free peptide, acetate salts and modified derivatives may share similar names |
| Does Selank affect GABA-related pathways? | Animal tissue and cultured-cell studies | Possible indirect modulation | No confirmed single human mechanism |
| Does Selank inhibit enkephalin-degrading enzymes? | In-vitro and animal evidence | Activity reported | Clinical significance is unknown |
| Does Selank alter BDNF? | Rat studies | Changes reported in selected models | No reliable proof of the same effect or outcome in humans |
| Has Selank been studied in people with anxiety symptoms? | Small comparative and add-on studies | Preliminary human evidence | Limited methodology, replication and international trial registration |
| Does Selank change brain connectivity? | Small healthy-volunteer fMRI study | Short-term signal changes reported | Connectivity is not a clinical benefit and the report was brief |
| Is long-term safety established? | Limited human publications | No | No large systematic safety programme or long-term pharmacovigilance identified |
| Is Selank approved as a UK medicine? | Official regulatory searches | No authorisation identified | Online availability does not indicate approval |
| Are research-market products equivalent to study material? | Product and analytical comparison | Equivalence cannot be assumed | Identity, impurities, concentration and formulation may differ |
Important Selank Research Limitations
The available publications do not support broad medical or wellbeing claims.
- Most human publications are small.
- Several important studies are available mainly in Russian.
- Study reporting does not consistently match modern CONSORT standards.
- Placebo control and blinding are not clear in several publications.
- Independent international replication is limited.
- No large UK clinical trial was identified.
- No established human pharmacokinetic programme was identified.
- Long-term safety information is inadequate.
- Rare adverse reactions cannot be assessed from small studies.
- Animal behavioural outcomes are often presented online as human benefits.
- Brain-connectivity changes do not prove improved mental health.
- Cytokine changes do not establish a desirable immune effect.
- Free Selank and modified Selank derivatives may be conflated.
- The exact substance used in older publications may not always be fully characterised.
- Online products may not match published research material.
- No approved UK indication was identified.
How Selank Research Material Should Be Analytically Assessed
A high-performance liquid chromatography percentage alone is not enough to establish identity or quality.
Intact Molecular Mass
Mass spectrometry should identify an ion pattern consistent with the declared Selank form.
Tandem Mass Spectrometry
Fragment-ion evidence should support the complete TKPRPGP sequence.
Free Peptide or Acetate
Documentation should distinguish free Selank from an acetate salt and from N-acetylated material.
Peptide Assay
Net peptide content should be quantified rather than inferred from total powder weight.
Related Substances
Chromatography should examine truncations, deletion sequences, oxidation and other synthesis-related impurities.
Higher-Molecular-Weight Species
Appropriate methods may be required to investigate aggregates that ordinary reverse-phase HPLC may not reveal.
Acetate Measurement
Acetate content should be measured where the material is described as Selank acetate.
Finished-Product Testing
A raw-material certificate does not necessarily describe the contents of the finished vial.
What a Meaningful Selank COA Should Include
- Full peptide sequence
- Declared terminal groups
- Exact salt or counterion
- Observed intact molecular mass
- Mass-spectrometry acceptance criteria
- Peptide-content assay
- Chromatographic purity
- Related-substance profile
- Acetate result where applicable
- Water and residual-solvent results
- Aggregation testing or a clear statement that it was not performed
- Finished-batch number
- Testing laboratory identity
- Method references and dates
- A clear list of tests not performed
Why “99% Purity” Does Not Prove Everything
A chromatographic purity percentage cannot by itself prove correct sequence, molecular form, peptide amount, acetate content, aggregation state, microbiological quality, stability or equivalence to research material used in a publication.
Selank Safety and Product-Quality Uncertainties
Limited adverse-event reporting should not be interpreted as proof of safety.
Human Safety Evidence Is Incomplete
Small human publications generally described Selank as tolerated within their study settings, but safety reporting was limited and follow-up periods were short.
Small trials are not capable of reliably detecting uncommon, delayed or population-specific adverse effects.
FDA Immunogenicity Concerns
FDA’s current compounding-safety information states that Selank acetate may pose immunogenicity risks for certain routes because of possible peptide aggregation and peptide-related impurities.
Immunogenicity means that the immune system recognises a product or impurity and generates a response. The consequences can range from laboratory antibody formation to clinically important reactions, although the actual risk for Selank remains insufficiently characterised.
Unknown Pharmacokinetics
Reliable public information concerning absorption, distribution, metabolism and elimination in diverse human populations is limited.
Without a mature pharmacokinetic programme, it is difficult to relate a concentration in a commercial product to tissue exposure or duration of biological activity.
Product-Specific Risks
- Incorrect sequence
- Incorrect salt or modified derivative
- Peptide truncations
- Oxidation or other degradation
- Aggregation
- Incorrect net quantity
- Residual synthesis reagents or solvents
- Unverified microbiological quality
- Unverified bacterial-endotoxin control
- Inaccurate or mismatched certificates
- Uncontrolled storage or transport
Unknown does not mean harmless
The absence of a large adverse-event database may reflect limited regulated exposure and weak surveillance rather than an established absence of risk.
Selank and Peptides UK Regulation
Regulatory information checked on 21 July 2026.
No UK Marketing Authorisation Identified
No current UK marketing authorisation for Selank, Selank acetate or a modified Selank derivative was identified in the official medicine sources searched for this article.
Selank should not be presented as an approved UK medicine for anxiety, stress, depression, cognitive impairment, sleep disturbance, immune conditions or neurological disease.
The existence of foreign publications, international sellers or laboratory catalogues does not create UK authorisation.
How the MHRA Assesses a Product
MHRA guidance explains that a product may be considered medicinal where it is presented as preventing or treating disease, or where it is intended to restore, correct or modify a physiological function through pharmacological, immunological or metabolic action.
The MHRA may consider explicit claims, implied claims, ingredient properties, product name, packaging, websites, social-media content, intended use and customer reviews.
A “Research Use Only” statement does not necessarily determine classification where the wider presentation promotes personal use or makes anxiety, mood, sleep, cognitive or neurological claims.
Advertising Restrictions
The Human Medicines Regulations restrict advertising medicinal products where the necessary marketing authorisation, registration or certificate is not in force.
This section provides general regulatory education and does not constitute legal advice.
US Regulatory Context
FDA lists Selank acetate among withdrawn compounding nominations associated with potential significant safety concerns. The agency highlights possible immunogenicity from aggregation or peptide-related impurities and states that important human safety information is lacking.
FDA’s compounding position is a United States regulatory matter. It does not determine UK law, but it provides relevant evidence about the current characterisation and safety gaps.
Common Selank Claims Examined
Many online statements convert preliminary research observations into unsupported conclusions.
“Selank is a proven anxiety treatment.”
Small comparative studies reported changes in anxiety rating scales.
The evidence lacks the scale, independent replication, placebo control and regulatory review needed to establish an approved UK treatment.
“Selank increases GABA.”
Animal gene-expression studies suggest a relationship with GABA-related signalling.
The mechanism appears indirect and complex. A cultured human-cell study did not find direct changes in the selected GABAergic gene transcripts.
“Selank improves memory.”
Animal learning and memory experiments reported changes under selected conditions.
These results do not demonstrate reliable improvement in human memory, academic performance or cognitive impairment.
“Selank raises BDNF.”
Rat research reported changes in hippocampal BDNF expression or content.
This does not prove a desirable BDNF effect in humans or establish a clinical neurological benefit.
“Selank regulates immunity.”
Laboratory, animal and small human studies measured cytokine or immune-gene changes.
Altering an immune marker is not automatically beneficial and does not establish treatment of an immune condition.
“Selank works without sedation or dependence.”
Some small studies did not report the same sedative pattern associated with benzodiazepines.
The available evidence is not sufficient to establish long-term absence of sedation, tolerance, withdrawal or dependence-related effects.
“N-acetyl Selank is simply stronger Selank.”
N-terminal acetylation creates a different chemical entity.
Selank studies cannot automatically establish the behaviour, safety or effectiveness of an acetylated or amidated derivative.
“Research-grade Selank is pharmaceutical grade.”
“Research grade” is not a UK medicinal-product approval category.
A laboratory purity result does not establish authorised manufacture, clinical suitability or compliance with medicinal-product standards.
Selank Compared With Tuftsin and Semax
These peptides are related by research history but are not interchangeable.
| Peptide | Sequence or Origin | Main Research Context | Important Distinction |
|---|---|---|---|
| Tuftsin | Thr-Lys-Pro-Arg | Immune-cell and immunoglobulin-fragment biology | Naturally occurring parent sequence |
| Selank | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Stress behaviour, neurotransmission and immune signalling | Synthetic seven-residue tuftsin analogue |
| Semax | Met-Glu-His-Phe-Pro-Gly-Pro | ACTH-fragment, cognition and neurological research | Different sequence and biological origin |
| N-acetyl Selank | Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro | Commercial and limited derivative research | Not chemically identical to standard Selank |
Selank and Semax both contain the C-terminal Pro-Gly-Pro sequence, but the first four residues differ. Findings involving one peptide should not be attributed to the other.
How to Assess Selank and Peptides UK Evidence Critically
Use this checklist before accepting a scientific or commercial statement.
- Does the source state the complete TKPRPGP sequence?
- Does it distinguish free Selank from Selank acetate?
- Does it distinguish acetate salt from N-terminal acetylation?
- Was the research conducted in humans?
- How many people took part?
- Was there a placebo group?
- Was allocation randomised?
- Were participants and assessors blinded?
- Was the trial registered in advance?
- Were outcomes specified before analysis?
- Has the result been independently replicated?
- Was the study published in full?
- Was the study material chemically characterised?
- Does an animal behaviour result become a human claim?
- Is an fMRI signal presented as proof of improvement?
- Are safety and adverse-event details provided?
- Does the COA match the finished batch?
- Were aggregates and related substances tested?
- Is the author also selling Selank?
- Is the claimed use authorised in the UK?
Medical and Editorial Review
This final article has been reviewed for medical context, evidence presentation, patient safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.
Read professional profileSelank Peptide UK Frequently Asked Questions
Evidence-led answers about Selank identity, research, safety and UK regulation.
What is Selank?
Selank is a synthetic seven-amino-acid peptide derived from the sequence of the naturally occurring peptide tuftsin.
What is the Selank amino-acid sequence?
Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, abbreviated TKPRPGP.
Is Selank naturally occurring?
No. The complete seven-residue Selank molecule is synthetic, although its first four residues reproduce the naturally occurring tuftsin sequence.
What is tuftsin?
Tuftsin is the tetrapeptide Thr-Lys-Pro-Arg, historically studied in relation to immunoglobulin-derived immune signalling.
Is Selank an approved anxiety medicine in the UK?
No UK marketing authorisation for Selank was identified in the official medicine sources searched for this article.
Has Selank been studied in humans?
Yes. Several small studies investigated anxiety-spectrum symptoms, biochemical markers and brain functional connectivity. The evidence remains preliminary and methodologically limited.
Was Selank compared with phenazepam?
A Russian-language comparative study involving 60 patients compared reported outcomes associated with Selank and phenazepam. The publication does not provide the level of confirmatory evidence required for UK approval.
Does Selank increase GABA?
Research suggests possible modulation of GABA-related signalling, but it has not established that Selank simply increases GABA concentrations in humans.
Does Selank change BDNF?
Rat studies reported changes in BDNF expression or content under selected experimental conditions. Equivalent clinically meaningful effects in humans have not been established.
Has Selank been studied for memory?
Animal learning and memory studies exist. They do not prove improvement in human memory or treatment of cognitive impairment.
Is Selank an immunomodulator?
Selank has altered cytokine and immune-gene measurements in research settings. These observations do not establish a safe or useful immune treatment.
What is Selank acetate?
Selank acetate is a salt form in which Selank is associated with acetate as a counterion.
Is Selank acetate the same as N-acetyl Selank?
No. An acetate salt involves a counterion, while N-acetyl Selank contains a covalently attached acetyl group at the peptide’s N-terminus.
Is N-acetyl Selank amidate the same as Selank?
No. It is a modified derivative with terminal chemical changes and should be treated as a distinct research material.
What did the FDA say about Selank acetate?
FDA states that compounded Selank acetate may present immunogenicity risks because of possible aggregation and peptide-related impurities, while important human safety information remains lacking.
Are the long-term risks known?
No. A large, systematic and long-term human safety programme was not identified.
Does 99% HPLC prove that a Selank vial is genuine?
No. It does not by itself prove the complete sequence, correct derivative, peptide quantity, counterion, aggregation state or microbiological quality.
What should a Selank COA include?
It should include sequence, terminal groups, chemical form, molecular-mass results, peptide assay, chromatography, related substances, counterion results and batch information.
Does “Research Use Only” make Selank legal for personal use?
No. UK classification may depend on the complete presentation, claims, intended purpose and pharmacological context.
Is Selank the same as Semax?
No. They are different seven-residue peptides with different parent sequences and research histories.
Does this article provide dosing or nasal-use instructions?
No. It does not provide preparation, administration, dosing, nasal-use, injection, cycling or personal-experimentation instructions.
Key Takeaways
- Selank is a synthetic seven-residue analogue of the natural peptide tuftsin.
- Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro.
- Research has examined GABA-related signalling, enkephalin metabolism, BDNF and immune-gene expression.
- Most mechanistic findings come from laboratory and animal studies.
- Small human studies reported changes in anxiety measures and brain connectivity.
- The human evidence is not sufficiently large, independently replicated or methodologically robust for firm clinical conclusions.
- No UK marketing authorisation was identified.
- FDA highlights potential immunogenicity and product-characterisation concerns for Selank acetate.
- Free Selank, Selank acetate and modified Selank derivatives are not chemically interchangeable.
- A purity percentage alone cannot establish identity, quantity or safety.
- Research-market products should not be assumed to match material used in published studies.
- Selank should not be promoted as an approved UK treatment.
Relevant It’s Me & You Clinic Peptides UK Resources
Explore related evidence-led resources and practitioner profiles.
Semax UK
Compare Selank with the separate ACTH-derived research peptide Semax.
Browse related peptide guidesResearch Peptides UK
Browse the wider educational series on peptide identity, research evidence and UK regulation.
Browse the Peptides UK education libraryDr Snieguole Geige
Learn more about the clinic’s medical and patient-education adviser.
View Dr Snieguole Geige’s profileDr Rimas Geiga
Explore Dr Rimas Geiga’s evidence-led approach to health, wellbeing and scientific literacy.
View Dr Rimas Geiga’s profileReferences
- PubChem. Selank, CID 11765600. PubChem compound record
- PubChem. Selank acetate, CID 155489759. PubChem compound record
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. FDA safety information
- Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014;114(7):17–22. PMID: 25176261. PubMed record
- Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with Selank. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(6):33–40. doi:10.17116/jnevro20151156133-40. PMID: 26356395. PubMed record
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalised anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38–48. PMID: 18454096. PubMed record
- Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Nurbakhsh TK. Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders. 2008. PMID: 18577961. PubMed record
- Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences. 2020;490(1):9–11. doi:10.1134/S001249662001007X. PMID: 32342318. PubMed record
- Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology. 2016;7:31. PMID: 26924987. PubMed record
- Filatova E, Shadrina M, Slominsky P. GABA, Selank and olanzapine affect expression of genes involved in GABAergic neurotransmission in different ways. 2017. PMID: 28293190. PubMed record
- Kost NV, Sokolov OY, Gabaeva MV, et al. Semax and Selank inhibit enkephalin-degrading enzymes from human serum. 2001. PMID: 11443939. PubMed record
- Zozulya AA, Sokolov OY, Kost NV, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. 2001. PMID: 11550013. PubMed record
- Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. 2008. PMID: 18841804. PubMed record
- Kolik LG, Nadorova AV, Antipova TA, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex in rats. Bulletin of Experimental Biology and Medicine. 2019;167(5):641–644. doi:10.1007/s10517-019-04588-9. PMID: 31625062. PubMed record
- Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. 2003. PMID: 14552529. PubMed record
- Vyunova TV, Andreeva LA, Shevchenko KV, et al. The molecular aspects of heptapeptide Selank biological activity. 2018. PMID: 30255741. PubMed record
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA guidance
- Human Medicines Regulations 2012, Regulation 279. Legislation.gov.uk
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025. UKAS guidance
